ライフサイエンスコーパス: test drug

1 ression throughout the years or evaluate any tested drugs.

2 s between these two methods was 100% for all tested drugs.

3 This study also highlights the importance of testing drug activity in biological matrices as well as

4 predicted long-term recovery better than any tested drug after thoracic SCI in rats.

5 Investigating how a test drug alters the reaction of a site-directed electro

6 ormed before and after the first dose of the test drug and again after 4 weeks of therapy.

7 tudy methods to manipulate hemorrhage and to test drugs and devices for safety, because the rabbit mo

8 e, parasite tropism, and pathogenesis and to test drugs and vaccines against naturally acquired VL.

9 86N mutation increased resistance to all the tested drugs and augmented the effect of G185V on etopos

10 Administration (FDA)-approved or clinically tested drugs and identified drugs that synergize to inhi

11 In a total of 22 tested drugs and metabolites, 21 analytes were detected

12 opens new opportunities to develop vaccines, test drugs, and clone parasites for genome sequencing.

13 rdization, starting with the most frequently tested drugs, BL antibiotics.

14 Phase II studies have tested drugs blocking EGFR, vascular endothelial growth

15 es such as the NCI-60 have long been used to test drug candidates for their ability to inhibit prolif

16 Among tested drugs, cefoxitin and tigecycline showed promising

17 gy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, reviewed

18 at approximately 50% of neurite tips at all tested drug concentrations (1-10 muM).

19 idic tools allow new ways to manufacture and test drug delivery systems.

20 ity of spheroids as an in vitro platform for testing drug delivery systems.

21 ited 90% of the isolates for the majority of tested drug-dermatophyte combinations.

22 ar and angiogenic neoplasias, as well as for testing drugs designed to curtail aberrant EC growth.

23 cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling.

24 ensitive, robust, and efficient platform for testing drug effectiveness and for arrhythmia screening.

25 This allowed us to test drug effects, expectancy (knowledge) effects, and t

26 involved in bone colonization and to rapidly test drug efficacies on bone micrometastases.

27 the in vivo tumor microenvironment; and (4) test drug efficiency in an in vitro model that is compar

28 All test drugs evoke fluoxetine-sensitive efflux of [(3)H]5-

29 is mouse model provides an important tool to test drugs for their potential to cause hemolytic toxici

30 Rats were then tested drug free during an extinction test.

31 ats were conditioned with 1.0 mg/kg AMPH and tested, drug free, 72 h after the last conditioning sess

32 However, when rats were tested drug-free 24 h after OFC inactivation and reversa

33 g in sustained freezing when mice were later tested drug-free.

34 However, the tested drugs have limited specificity and efficacy so th

35 The main problem was to retain the test drug in situ without extraneous irritation from the

36 The effects of the test drugs on COX-2 and PPAR gamma expression and on the

37 al, jugular catheters were injected with the test drug or 0.9% NaCl (saline), and blood samples were

38 hospecific antibodies responded similarly to test drugs or light.

39 ing mechanistic studies and, if refined, for testing drugs or small molecules for personalized medici

40 udying the mechanism of this disease and for testing drugs or therapies for treating osteoarthritis.

41 In all three tested drug pairs, the alternating treatment reduced the

42 echanisms, identify therapeutic targets, and test drugs pre-clinically.

43 This study confirms that although all three test drugs produced significant antinociception at 10 mi

44 Exercise testing, drug provocation, advanced cardiac imaging, and

45 he population of bacteria susceptible to the test drug, S the population susceptible only to steriliz

46 Adequate infrastructure for testing drug sensitivity and sufficient evidence of firs

47 mercially available recombinant virus assays test drug susceptibility of virus pools.

48 atform is simple to operate and multiplex to test drugs targeting angiogenesis in a more physiologica

49 ht opens the possibility of using clinically tested drugs, targeting the Wnt/beta-catenin pathway, fo

50 ng ways to improve respiration after SCI, we tested drugs that stimulate serotonin 1A (5-HT1A) recept

51 sed biomarkers in clinical trials as well as testing drugs that modulate APP processing as potential

52 hology in vitro represents a new approach to testing drugs that will help accelerate the development

53 cell preparations, the selectivities of the tested drugs toward endothelial cell over platelet COX-1

54 eir applications to model liver diseases and test drug toxicity in vitro.

55 armaceutical company policies that routinely test drugs under development; if a candidate drug shows

56 mpathetic nerves innervating the ventricles, test drugs were introduced into the pericardial sac for

57 Mini 11 gave LOQs of 10-20 ng mL(-1) for the tested drugs, which is sufficient to cover the therapeut

58 To establish a preclinical animal model for testing drugs with potential effects on myeloproliferati